Amwill Healthcare IPO had a weak stock market Listed on February 12, listing at a 19.95% discount on the BSE SME platform. The stock opened at ₹88.85 per share, significantly lower than its issue price of ₹111 apiece, reflecting subdued investor sentiment.
The Amwill Healthcare IPO was subscribed 5.73 times overall, with strong demand from Qualified Institutions (7.8x), Non-Institutional Buyers (5.66x), and Retail Investors (4.77x). A total of 9,413 applications were received, with bids for 2.94 crore shares, amounting to ₹326.41 crore.
Amwill Healthcare IPO had a disappointing debut, listing at ₹88.85, 19.95% lower than its issue price of ₹111. The last GMP was ₹0, indicating no premium in the grey market. Despite an expected listing price of ₹111 as per GMP, the stock opened below expectations, marking a negative listing.
Overview of Contents
Details About Amwill Health Care IPO
Amwill Healthcare IPO will open for subscription from February 5 to February 7, 2025, aiming to raise ₹59.98 crore, including a fresh issue of ₹48.88 crore and an offer for sale of 10 lakh shares. The price band is set at ₹105-₹111 per share.
The IPO allocation is 35% for retail investors, 50% for QIBs, and 15% for HNIs. Retail investors must invest a minimum of ₹1,05,000 (1,000 shares), while HNIs need ₹2,10,000 (2,000 shares). Allotment will be finalized on February 10, 2025, with listing on NSE on February 12, 2025.
Funds Deployment of Amwill Healthcare IPO
- A portion of the funds will be used to finalize the Offer Price before filing with the ROC.
- The remaining funds, up to 25% of the Gross Proceeds, will be used for general corporate purposes.
About Company
Amwill Healthcare Limited, founded in August 2017, specializes in derma-cosmetic product development, partnering with contract manufacturers and distributors. Its portfolio includes solutions for acne, fungal infections, anti-aging, and vitiligo. With a strong presence in Karnataka, Andhra Pradesh, and Telangana, the company follows an asset-light model to ensure high-quality formulations. Recent launches of seven new products further expand its offerings in the skincare sector.
Amwill healthcare Financial Performance
Amwill Healthcare’s financial growth has been strong, with revenue rising from ₹18 Cr in 2021 to ₹35.79 Cr by December 2023. The company turned profitable in 2022, with ₹2.57 Cr PAT, growing to ₹11 Cr in December 2023. Assets increased from ₹1.02 Cr in 2021 to ₹14.67 Cr, reflecting its expanding business and improved profitability.